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Abstract. Background/Aim: This study investigated the
clinicopathological factors associated with outcomes in
patients with Luminal A breast cancer. Patients and
Methods: Retrospective analysis of the association of
clinicopathological factors and breast cancer outcome in
421 patients with newly diagnosed Luminal-A breast cancer
that were enrolled from January 2008 to December 2014.
Clinicopathological data were analyzed to validate the
relationship with disease free survival (DFS) and overall
survival (OS). Kaplan-Meier curves and log-rank tests were
used to analyze the value of clinicopathological factors
(tumor size, node status and lymphovascular invasion), and
subsequent Cox regression analysis revealed significant
prognostic factors. Results: With a median of 61 months
follow up, the 5-year DFS and 5-year OS rate were 98.3%
and 99.3%. Cox multivariate regression analysis showed that
clinical anatomic stage, tumor size, status of lymph nodes,
lymphovascular invasion and systemic treatment are strong
prognostic factors for clinical outcome in patients with
Luminal-A breast cancer. Of all 413 patients with stage I-III
breast cancer, 14 presented with metastasis (3.4%) during
the follow up. Bone (6/14, 42.9%) was the most common site
of metastasis followed by liver (5/14, 35.7%) and lung (4/14,
28.6%). The median survival time after metastasis was 20.4
months. Of all the sites of distant metastasis, liver metastasis
was the only factor that affected survival time after
metastasis (χ2=6.263, p=0.012). Conclusion: Patients with
Luminal A breast cancer have excellent outcomes. Liver
metastasis is an important factor compressing the survival
time after distant metastasis presents.
Nowadays, the five most commonly diagnosed cancers
among women in China are breast, lung and bronchus,
stomach, colorectal, and esophageal. Breast cancer accounted
for 15% of all newly diagnosed invasive cancer cases in
China in 2015. Amongst Chinese women in the age group
30-59 years breast cancer is the most commonly diagnosed
cancer and is the leading cause of cancer death in women
younger than 45 years old (1). Studies have shown that the
mortality trend of breast cancer has increased in Chinese
women between 1990 and 2009 (2). Nearly 10 years have
passed since 2009 and there have been fundamental changes
in the understanding of breast cancer biology and treatment
strategies. Disease free survival and overall survival of breast
cancer patients have also changed.
Breast cancer is identified by molecular biomarkers and
classified into four different subtypes: Luminal A, Luminal
B, HER2 overexpression and Triple Negative breast cancer.
Due to ER and PR positive, HER2 negative and low Ki67
expression, Luminal A breast cancer has lower recurrence
risk and better prognosis than the other molecular subtypes.
In order to explore factors related with local recurrence and
metastasis, a retrospective study was conducted to analyze
clinicopathological factors to predict disease progression of
patients with Luminal A breast cancer.
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Patients and Methods
Between January 2008 and December 2014, patients with newly
diagnosed Luminal A breast cancer at the Breast Disease Center,
Peking University First Hospital were enrolled. All were diagnosed
by core needle biopsy (CNB) prior to treatment. Patients were
excluded if clinicopathological data or follow-up information were
unavailable. A total of 421 patients were enrolled in this
retrospective study. Patients’ anatomic stages and prognostic stages
were restaged by the American Joint Committee on Cancer (AJCC)
8th edition breast cancer staging system.
Immunohistochemistry (IHC) and tumor grade of breast cancer.
Immunohistochemical (IHC) examination was routinely performed
on breast cancer specimens obtained from CNB or surgery. IHC
testing was performed according to the American Society of Clinical
Oncology/College of American Pathologists guidelines (3, 4). ER
and PR positive status was defined as there being at least 1%
positive nuclei in the sample. HER2-positive status was defined as
IHC 3+ or FISH over-expression. Ki67 was measured in terms of
its nuclear staining, the percentage of Ki67 positive cells were
calculated as the percentage of MIB-1-positive cells in a total of
1000 malignant cells observed at high-power magnification (×400).
The histologic grade was determined using the modified Scarff–
Bloom–Richardson grading system (Nottingham Combined
Histologic Grade).
Molecular subtypes of breast cancer. Luminal A breast cancer was
defined as ER and/or PR positive, HER-2 negative, Ki-67<14%
according to the St. Gallen Consensus, 2011(5).
Treatment of patients. All patients received surgery (mastectomy or
breast conserving surgery) and/or chemotherapy (neoadjuvant or
adjuvant) followed by endocrine therapy. Radiation therapy was
administered to patients who received breast conserving surgery or
who had lymph-node metastasis. Sentinel lymph node biopsy was
used to evaluate status of axillary lymph nodes. Patients with
positive sentinel lymph node, or any lymph node metastasis proved
by CNB prior to surgery, received axillary lymph node dissection.
Follow-up. All patients enrolled in this study had complete follow
up information. Disease free survival (DFS) was defined as the
interval from surgery to disease recurrence, either loco-regional or
distant metastasis, or the date of last follow-up without any evidence
of recurrence. Overall survival (OS) was calculated from the date
of diagnosis of breast cancer to death or final follow-up.
Statistical analysis. Statistical comparisons of clinical outcomes,
cancer stage and other clinicopathological data were assessed with
SPSS software version19.0. The Kaplan-Meier method, log-rank test
and Cox multivariate regression analysis were used to evaluate the
differences between the anatomic staging subgroup and prognostic
staging subgroups. All of the statistical tests and p-values were two-
tailed. p<0.05 was considered statistically significant.
Results
Patient characteristics. From January 2008 to December
2014, 446 patients with Luminal A breast cancer were
diagnosed at the Breast Disease Center, Peking University
First Hospital, which accounted for 20.54% (446/2171) of all
patients diagnosed with breast cancer at the center. Twenty
five patients were excluded because the clinicopathological
data or follow-up information were unavailable. A total of
421 patients were finally enrolled in this retrospective study.
The median age of patients was 56 years old (24 to 91), with
8 cases (1.9%) under 35 years old, 293 cases (69.6%)
between 35 to 65, and 120 cases (28.5%) older than 65 years
old. Of all cases, 166 cases (39.4%) were premenopausal
women and 255(60.6%) were post-menopausal women. A
total of 106 cases (25.2%) underwent breast conserving
surgery and radiation therapy while the other 315 cases
underwent mastectomy. Fifty two cases (12.4%) underwent
neoadjuvant chemotherapy and surgery followed by
endocrine therapy, 102 cases (24.2%) underwent surgery
followed by adjuvant chemotherapy and endocrine therapy,
267 cases (63.4%) underwent surgery followed by endocrine
therapy alone. Median follow-up time of this group of
patients was 61 months (7 to 100 months). The rate of 5-year
disease free survival was 98.3% and rate of 5-year overall
survival (OS) was 99.3%.
The clinicopathological characteristics of patients. Of all
patients, 216 cases (51.3%) were clinical stage I, 155 cases
were clinical stage II (36.8%), 42 cases were clinical stage
III (10%) and 8 cases were clinical stage IV (1.9%). For
tumor size, 263 cases (62.5%) were T1, 140 cases (33.3%)
were T2, 15 cases (3.6%) were T3 and 3 cases (0.7%) were
T4. For lymph node status, 284 cases (67.5%) were negative,
100 cases (23.8%) were N1, 29 cases (6.9%) were N2 and 8
cases (1.9%) were N3. Two hundred and ninety cases
(68.9%) were histopathological grade I, 124 cases grade II
and 7 cases grade III. Four hundred and three cases (95.7%)
had no lymphovascular invasion whilst 18 cases (4.3%) had
lymphovascular invasion.
Correlation between clinicopathological characteristics and
prognosis. Cox multivariate regression analysis showed that
clinical stage (anatomic stage by AJCC cancer staging
manual, 8th edition), tumor size, lymph nodes status,
systemic treatment and lymphovascular invasion were factors
related with clinical outcome of Luminal A breast cancer.
Age, menopausal status, surgery and tumor grade were not
related with disease progression. Clinicopathological
characteristics of patients with Luminal A breast cancer
which were associated with clinical outcome are listed in
Table I.
The characteristics of patients with local recurrence and
distant metastasis. Of the 413 patients with stage I-III breast
cancer, 14 patients (3.4%) presented with local recurrence or
distant metastasis during follow-up, in which 2 cases
(14.3%) were pre-menopausal and 12 cases (85.7%) were
post-menopausal. The mean age of diagnosis amongst the 14
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patients was 65.5 years old (range=43-84), whilst the mean
age of recurrence was 70.5 years old (range=46-86). The
initial anatomic stage and prognostic stage as determined by
the 8th AJCC breast cancer staging system of 14 patients are
listed in Table II. Four patients had no differences between
their anatomic and prognostic stage. The characteristics of
metastasis and their clinical outcomes are also shown in
Table II. Two cases (14.3%) developed local recurrence,
whilst the other 12 (85.7%) presented with distant metastasis.
The most common site of distant metastasis was bone (6/14,
42.9%), followed by liver (5/14, 35.7%) and lung (4/14,
28.6%). Three cases (21.4%) presented with multi-site
metastasis when recurrence was diagnosed. For patients who
presented with single metastatic sites 4 patients were
Ye et al: The Impact of AJCC 8th Cancer Stage System on Luminal A Breast Cancer in China
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Table I. Clinicopathological characteristics associated with the prognosis of the Luminal A breast cancer patients.
                                                              N (%)               5-year DFS (%)               χ2                    p              5-year OS (%)                χ2                     p
AJCC anatomic stage                                                                                          11.933             0.003                                                4.606               0.203
    I                                                      216 (51.3)                     99.4                                                                        98.9                                                  
    II                                                     155 (36.8)                     91.9                                                                        96.8                                                  
    III                                                      42 (10)                         97                                                                          94.6                                                  
    IV                                                      8 (1.9)                                                                                                        85.7                                                  
T-stage                                                                                                                 11.521             0.009                                               23.626              0.000
    T1                                                   263 (62.5)                     98.6                                                                        99.1                                                  
    T2                                                   140 (33.3)                     92.1                                                                          95                                                    
    T3                                                     15 (3.6)                        100                                                                         100                                                   
    T4                                                      3 (0.7)                         100                                                                           50                                                    
Lymph node status                                                                                              20.532             0.000                                               14.234              0.003
    N0                                                  284 (67.5)                     99.2                                                                        97.9                                                  
    N1                                                  100 (23.8)                     90.7                                                                        97.4                                                  
    N2                                                    29 (6.9)                        100                                                                         100                                                   
    N3                                                     8 (1.9)                        83.3                                                                        72.9                                                  
Lymphvascular invasion                                                                                     14.029             0.000                                                5.957               0.015
    No                                                 403 (95.7%)                     97                                                                                                                                   
    Yes                                                  18 (4.3%)                      88.2                                                                                                                                  
System Treatment                                                                                                 4.287              0.117                                                6.179               0.046
    NAC+ET                                        52 (12.4)                      93.8                                                                          94                                                    
    AC+ET                                          102 (24.2)                       97                                                                            98                                                    
    ET                                                  267 (63.4)                     96.7                                                                        97.2                                                  
NAC: Neoadjuvant chemotherapy; AC: adjuvant chemotherapy; ET: endocrine therapy.
Table II. The characteristics of patients with metastasis and their DFS and OS.
Case no.      Anatomic stage       Prognostic stage                         Patterns of metastasis                          DFS (months)         OS (months)         Status
1                             IIA                            IB                                         Lung metastasis                                       71.9                        92.7                 alive
2                             IIA                            IB                                         Lung metastasis                                       58.1                        58.5                 dead
3                             IIB                            IIB                                        Local recurrence                                      46.3                        50.1                 dead
4                             IIB                            IB                                 Bone and liver metastasis                               45.5                        75.1                 dead
5                             IA                             IA                                         Bone metastasis                                       33.9                        88.7                 alive
6                            IIIC                          IIIB                                        Liver metastasis                                      34.6                        38.3                 dead
7                            IIIC                          IIIA                                        Liver metastasis                                      83.1                        87.6                 alive
8                             IIA                            IB                                Liver and Cecal metastasis                              31.7                        36.2                 dead
9                            IIA                            IB                                         Lung metastasis                                       13.6                        70.6                 alive
10                          IIA                            IB                                         Bone metastasis                                        4.0                         66.1                 alive
11                           IIB                            IB                                         Bone metastasis                                       40.0                        50.0                 alive
12                          IIA                            IB                                         Local recurrence                                      37.1                        47.2                 alive
13                           IIB                            IIB                    Bone, liver, lung and pancreas metastasis                  10.0                        27.2                 dead
14                           IIB                            IIB                                         Bone metastasis                                        6.0                         32.2                 alive
diagnosed with bone metastasis (28.6%), 3 cases with lung
metastasis (21.4%) and 2 cases with liver metastasis
(14.3%). 
The initial clinicopathological characteristics of patients
with metastasis and their survival time after metastasis. The
median survival time after metastasis diagnosed for the 14
Luminal A breast cancer patients was 20.4 (1 to 64) months.
TNM stage and lymph node status were predictors of
survival time after metastasis (χ2=12.666 and χ2=12.000,
p=0.002) (Table III). Age, menopausal status, tumor size,
tumor grade, surgical and systemic therapy had no
correlation with the survival time after metastasis.
Factors associated with survival time after metastasis in the
patients with metastasis. Six of 14 patients were under 65 years
old when they presented with metastasis; the other 8 patients
were over 65 years old. Four patients who presented with
metastasis did so within 24 months after treatment, whilst the
other 10 presented over 24 months after treatment. We
evaluated the correlation between factors such as age at
recurrence, DFS, number of recurrent sites and metastasis
patterns. There are statistical differences between patients with
liver metastasis and without liver metastasis (χ2=6.263,
p=0.012), the other factors had no correlation with survival time
after metastasis. One year survival rates of patients with liver,
bone and lung metastasis were 50%, 100% and 75%
respectively. Three-year survival rates of patients with liver,
bone and lung metastasis were 0%, 55.6% and 50%
respectively. The Kaplan-Meier curve of patients with liver
metastasis is shown in Figures 1-3. The 1-year and 3-year
survival rate of patients with distant metastasis were 72.7% and
47.7% (Figure 4). One year and 3-year survival rates of patients
with single site metastasis were 70% and 70% compared to
patients with multi-site metastasis (72.7% and 47.7%). The
patterns and characteristics of metastasis related to survival time
in patients with metastasis are showed in Table IV.
Discussion
Because of improvements in treatment and accurate
identification of patients at risk, long term survival can be
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Table III. The initial clinicopathological characteristics of patients with
metastasis and their correlation with the survival time after metastasis.
Characteristic                    N (%)        3-year survival       χ2             p
                                                             after metastasis 
                                                                      (%)
Age at diagnosis                                                                1.620      0.203
   ≤65                              7 (50.0%)              71.4                                  
   >65                              7 (50.0%)              25.0                                  
Menstrual status                                                                 2.729      0.520
   Premenopausal            2 (14.3%)               0.0                                   
   Postmenopausal         12 (85.7%)             54.5                                  
Breast Surgery                                                                   0.022      0.881
BCS                                2 (14.3%)                50                                    
Mastectomy                   12 (85.7%)             42.4                                  
AJCC Stage                                                                       12.666     0.002
   I                                    1 (7.0%)              100.0                                 
   II                                 11 (78.6%)             42.4                                  
   III                                2 (14.3%)               0.0                                   
Tumor size(mm)                                                                2.858      0.091
   ≤20                              3 (21.4%)             100.0                                 
   >20,≤50                      11 (78.6%)             25.0                                  
Lymph node status                                                            12.000     0.002
   N0                               5 (35.7%)              60.0                                  
   N1                               7 (50.0%)              35.7                                  
   N2                                0 (0.0%)                                                         
   N3                                1 (7.1%)                0.0                                   
Tumor Grade                                                                      1.742      0.187
   I                                   7 (50.0%)              62.5                                  
   II                                  7 (50.0%)              42.9                                  
   III                                 0 (0.0%)                                                         
Systemic Treatment                                                           1.240      0.538
   NAC+ET                     7 (50.0%)               0.0                                   
   AC+ET                       2 (14.3%)              50.0                                  
   ET alone                     5 (35.7%)              71.4                   
BCS: Breast conserving surgery; NAC: neoadjuvant chemotherapy, AC:
adjuvant chemotherapy, ET: endocrine therapy.
Table IV. The patterns and characteristics of metastasis and their
correlation with survival time in patients with metastasis.
Characteristic                    N (%)        3-year survival       χ2             p
                                                                   rate (%)
Age at recurrence                                                              0.756      0.385
   ≤65                              6 (42.8%)              66.8                                  
   >65                              8 (57.2%)              28.6                                  
DFS                                                                                    1.297      0.255
   ≤24 months                 4 (28.6%)              75.0                                  
   >24 months                10 (71.4%)             27.8                                  
Recurrent patterns                                                              0.135      0.713
   Local                           2 (14.3%)              50.0                                  
   Distant                        12 (85.7%)             47.7                                  
Numbers of 
recurrent sites                                                                     2.681      0.102
   Single                         11 (78.6%)               70                                    
   Multiple                      3 (21.4%)               0.0                                   
Bone metastasis                                                                 3.009      0.083
   Yes                               6 (42.9%)              55.6                                  
   No                               8 (57.1%)              42.9                                  
Liver metastasis                                                                 6.263      0.012
   Yes                               5 (35.7%)               0.0                                   
   No                               9 (64.3%)              77.8                                  
Lung metastasis                                                                 0.000      0.992
   Yes                               4 (28.6%)              50.0                                  
   No                              10 (71.4%)             44.4                                  
achieved in breast cancer patients. Based on the expression
of ER, PR, HER2 and Ki67, breast cancer is characterized
by its molecular biomarkers and classified into four different
subgroups: Luminal A, Luminal B, HER2 over-expression
and Triple Negative breast cancer (6). Due to high risk of
recurrence and poor prognosis, triple negative breast cancer
has attracted a lot of attention in both clinical practice and
research. Similarly, research has focused on the
mechanism(s) and acquired treatment resistance of target
therapies for HER2 positive breast cancer. Patients with
hormone-receptor positive, HER2 negative and low
expression of Ki67 breast cancer have favorable prognosis
compared with other subtypes, and thus the pattern of
metastasis in this subgroup has not been paid much attention.
Of all 421 Luminal A breast cancer patients enrolled in the
analysis, the 5-year DFS was 98.3%, and 5-year OS was
99.3%. However, there were still 14 patients (3.4%) who
developed local recurrence or distant metastasis during
follow-up, of which 4 patients presented with metastasis
within 2 years after treatment. So it is essential to focus on
the clinicopathological characteristics of Luminal A breast
cancer and its patterns of metastasis, as well as to evaluate
factors related with the survival time after metastasis. Thus
we can identify patients of high recurrence risk who need
escalated treatment to reduce the risk of metastasis and
associated mortality.
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Figure 2. Survival time after metastasis for patients with bone
metastasis. One year survival rates of patients with bone metastasis
were 100%. Three-year survival rates of patients with bone metastasis
were 55.6%. There was no statistical difference between patients with
bone metastasis and without bone metastasis in survival time after
metastasis (χ2=3.009, p=0.083).
Figure 1. Survival time after metastasis for patients with liver
metastasis. One-year survival rate of patients with liver metastasis was
only 50%, and no patients survived longer than 3 years. In contrast,
three-year survival rate of patients without liver metastasis was 77.8%
after metastasis were detected. There was statistical difference between
patients with liver metastasis and without liver metastasis in survival
time after metastasis (χ2=6.263, p=0.012).
We summarized the clinicopathological characteristics of
patients and retrospectively analyzed their correlation with
clinical outcomes of Luminal A breast cancer. Patients with
Luminal A breast cancer accounted for 20.54% of all breast
cancer patients during the same period in our center,
consistent with 21.7% reported by Ahn et al. (7). Median age
of the 421 patients with Luminal A breast cancer was 56 (24
to 91) years old, of which 293 patients (69.6%) were
between 35 to 65 years old, indicating that the age of
diagnosis with breast cancer is relatively young in Chinese
women, and the proportion of pre-menopausal patients is
also relatively high (pre-menopause 39.4% vs. menopause
60.6%). Clinical stage, tumor size, lymph node status,
systemic treatment and lymphovascular invasion are factors
related with clinical outcome in patients with Luminal A
breast cancer, whilst age, menstrual status, surgical
procedure and tumor grade were not associated with
prognosis. Despite 21-gene recurrence scores were not
available, clinicopathological characteristics are still
important predictive factors for the risk of metastasis in
Luminal A breast cancer, and can be used to determine the
need for adjuvant systemic therapy.
Few studies have discussed the clinicopathological
characteristics of patients with luminal A breast cancer who
presented with metastasis, and the impact of such
characteristics on survival time after metastasis. There were
14 patients within the 413 patients of stage I-III Luminal A
breast cancer patients who presented with metastasis in our
ANTICANCER RESEARCH 37: xxx-xxx (2017)
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Figure 3. Survival time after metastasis for the patients with lung
metastasis. One-year survival rates of patients with lung metastasis
were 75%. Three-year survival rates of patients with lung metastasis
were 50%. There was no statistical difference between patients with
lung metastasis and without lung metastasis in survival time after
metastasis (χ2=0.000, p=0.992).
Figure 4. Survival time after metastasis for the patients with local
recurrence and distant metastasis. Survival time after metastasis for the
patients with local recurrence and distant metastasis. The one-year and
three-year survival rate of patients with distant metastasis were 72.7%
and 47.7%. There was no statistical difference between patients with
local recurrence and distant metastasis in survival time after metastasis
(χ2=0.135, p=0.713).
study. We analyzed the clinicopathological characteristics at
initial diagnosis and after detection of metastasis, in order to
identify the clinical utility in predicting survival time after
metastasis. As our study showed, there were 2 patients who
presented with local recurrence and 12 patients who presented
with distant metastasis, of which 3 (21.4%) suffered from
multi-site metastasis. The cases presenting bone, lung and
liver metastasis alone were 4 (28.6%), 3 (21.4%) and 2
(14.3%) respectively. The most common site of distant
metastasis was bone (6/14, 42.9%), followed by liver (5/14,
35.7%) and lung (4/14, 28.6%). It is suggested that
monitoring these organs as standard care during follow-up
would allow for the detection of metastasis earlier. Although
Luminal A breast cancer has favorable prognosis, patients
who presented with metastasis suffered from a relatively short
survival time, especially those with liver metastasis. The
average survival time after metastasis was 20.4 months (1 to
64 months), but the 1-year survival rate of patients with liver
metastasis was only 50%, and no one survived longer than 3
years. In contrast, the 3-year survival rate of patients without
liver metastasis was 77.8% after metastasis was detected.
There was a statistical difference between patients with liver
metastasis and without liver metastasis in survival time after
metastasis (χ2=6.263, p=0.012).
Endocrine therapy is the preferred systemic therapy for
Luminal A breast cancer, but for those who are at risk of
local recurrence and distant metastasis, such as patients with
a large tumor, positive lymph nodes, high tumor grade or
lymphovascular invasion, adjuvant chemotherapy is still a
necessary therapy to achieve better prognosis. Therefore,
accurate evaluation of disease stages and recurrence risk is
important to make therapeutic decisions. Netanely et al. (8)
divided Luminal A breast cancer into two different
prognostic groups using RNA-Seq and DNA methylation
data. The analysis of these data provided two prognostic
gene panels that dissect and explain tumor variability within
Luminal A breast cancer which contributed to the
advancement of subtype-specific diagnosis and treatment.
However, limited evidence has confirmed the clinical
usefulness of this assay. The AJCC 8th breast cancer staging
system suggests multigene panel testing being routinely
performed and acts as part of the prognostic staging system
with biological markers including ER, PR, HER2, and tumor
grade to provide more information about disease prognosis
(9). The 21-gene assay can predict patients who could benefit
from adjuvant chemotherapy. Patients with low recurrence
scores (RS<11) can safely avoid adjuvant chemotherapy, but
adjuvant chemotherapy must be taken into consideration for
those with high recurrence score (RS>25). Disparities in
access and high cost make it difficult to maximize the
clinical utility of multigene panels in China. 
By adding important biological factors (HR status, HER2
status, tumor grade and gene panels) to TNM staging system,
the AJCC 8th edition puts forward a breast cancer prognostic
staging system, which differs from the original anatomic
stages in some patients. In the14 patients with Luminal A
breast cancer who presented with metastasis, 10 of whom
down staged according to prognostic staging system of AJCC
8th edition compared to their anatomic stages (Table II).
These patients had received chemotherapy according to their
original anatomic stages by the AJCC 7th edition cancer
staging system, though it appears they didn’t benefit from
chemotherapy. With this new prognostic staging system, they
might have had the chance to de-escalate chemotherapy so
as to reduce unnecessary adverse effects.
Precise disease staging is the way to personalized
treatment, especially in Luminal A breast cancer, which has
a more favorable prognosis than any other subtypes. The
clinicopathological information such as tumor size, status of
lymph nodes are still the basis of the breast cancer staging
system, together with biological markers and multigene
panels, we can learn more about the extrinsic and intrinsic
characteristics of tumors and make treatments more
personalized.
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